By: Jo Stephenson From: nursingtimes.net The National Institute for Health and Care Excellence published draft guidance recommending the drug neratinib as an extra treatment for a form of HER2-positive breast cancer. HER2-postitve breast cancer is a type of breast cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2), which promotes the growth of cancer …
Where Does T-DM1 Fit In First-Line Treatment for HER2-Positive Breast Cancer?
By: Dave Levitan From: www.cancernetwork.com Trastuzumab emtansine (T-DM1) with or without pertuzumab yielded good overall survival in patients with HER2-positive metastatic breast cancer according to the results of a phase III trial published in Cancer. Though these were not superior to survival seen with taxane-based therapy, T-DM1 should be considered an option for first-line therapy in patients deemed unsuitable for …
6 months treatment with Herceptin is as good as 12 months for preventing breast cancer return
By: Peter Thorley, University of Warwick From: medicalxpress.com A new study co-led by the University of Warwick Clinical Trials Unit has shown that shortening the duration of a therapy for breast cancer patients does not increase the risk of their cancer returning. The majority of clinical trials in cancer assess either new treatments or additional treatments to the current standard …
Phase III NALA Trial Results in Higher PFS With Neratinib Combo for HER2+ Breast Cancer
By: Jason M. Broderick From: targetedonc.com Combining Neratinib (Nerlynx) with capecitabine (Xeloda) showed a 24% reduction in the risk of disease progression or death compared with lapatinib (Tykerb) plus capecitabine in patients with HER2-positive metastatic breast cancer who had previously received 2 lines of HER2-targeted therapy, according to the results of the phase III NALA trial presented at the 2019 …
MacroGenics Announces Positive Results from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer
Study meets first sequential primary endpoint of progression-free survival (PFS) in head-to-head with current standard of care (trastuzumab and chemotherapy) MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced additional details of the results from the Phase 3 SOPHIA study of margetuximab in patients with …
Study uncovers unknown pathway for breast cancer recurrence
From: business-standard.com The researchers have tracked treatment-resistant cancer cells that grow and spread after the breast cancer treatment. For many women who thought they had beaten breast cancer, the news that it has roared back years later comes as an especially cruel diagnosis with no clear answers for why or how it recurs. Now a team of researchers has filled …
Breast cancer study by UCR medical student could help patients live longer
By: Iqbal Pittalwala From: ucr.edu A student at the University of California, Riverside, presented research results at the annual meeting of the American Association for Cancer Research, or AACR, in Atlanta showing that surgery is associated with higher survival rates for patients with HER2-positive stage 4 breast cancer compared with those who did not undergo surgery. The protein HER2, or …
Breast cancer drug approved for Australia
By: AAP From: 9news.com.au Kate Harper wants to be around to watch her two young twin sons grow up. That’s why, after grappling with the feeling of helplessness that came with being diagnosed with breast cancer, she made a commitment. “I said right from the start – and my husband’s in agreement as well – that we would attack everything …
Subcutaneous Herceptin Combo Therapy for Certain Breast Cancer Patients Granted FDA Approval
By: Jennifer Barrett From: pharmacytimes.com Officials with the FDA have approved trastuzumab and hyaluronidase-oysk (Herceptin Hylecta, Genentech) subcutaneous injection for certain patients with HER2-positive early and metastatic breast cancer, according to a press release. Trastuzumab and hyaluronidase-oysk is indicated for patients with early disease in combination with chemotherapy, and metastatic disease in combination with paclitaxel, or alone in patients who …
Collaboration Promises Better, More Accurate Breast Cancer Diagnostics
From: PR Newswire Data-sharing result s in an improved method of HER2 protein analysis which promises more accurate breast cancer diagnosis results. The Health Exchange Market, or T.H.E.M.™, together with LabCorp, Konica Minolta, Inc. University of Rochester, Penn State Hershey Medical Center and Lebanon VA Medical Center, has presented significant findings in breast cancer research at the 2018 San Antonio …
